Product nameAnti-OSMR antibody
See all OSMR primary antibodies
DescriptionRabbit polyclonal to OSMR
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Human
Fusion protein corresponding to Human OSMR aa 30-330.
Database link: Q99650
- 293T, HeLa, HepG2 and Raji cell lysates; Mouse lung and heart lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.3
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- HeLa whole cell lysate (ab150035)
- HepG2 whole cell lysate (ab166833)
- Mouse lung normal tissue lysate - total protein (ab29297)
- HeLa whole cell lysate (ab29545)
- Raji whole cell lysate (ab30124)
- Mouse heart normal tissue lysate - total protein (ab30291)
- HepG2 whole cell lysate (ab7900)
- 293T whole cell lysate (ab95494)
Our Abpromise guarantee covers the use of ab210771 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2000. Predicted molecular weight: 111 kDa.|
FunctionAssociates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events.
Tissue specificityExpressed at relatively high levels in all neural cells as well as fibroblast, epithelial and a variety of tumor cell lines.
Involvement in diseaseAmyloidosis, primary localized cutaneous, 1 (PLCA1) [MIM:105250]: A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins. Note=The disease is caused by mutations affecting the gene represented in this entry.
Sequence similaritiesBelongs to the type I cytokine receptor family. Type 2 subfamily.
Contains 4 fibronectin type-III domains.
DomainThe WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
The box 1 motif is required for JAK interaction and/or activation.
- Information by UniProt
- IL-31 receptor subunit beta antibody
- IL-31R subunit beta antibody
- IL-31R-beta antibody
ab210771 has not yet been referenced specifically in any publications.